
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Beyond Celiac Investments
Deal Size : Undisclosed
Deal Type : Financing
Beyond Celiac Investments Funds RheumaGen for Celiac Disease Cure Acceleration
Details : The financing will support the development of a novel cell & gene therapy for celiac disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Beyond Celiac Investments
Deal Size : Undisclosed
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RG0401
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : RheumaGen
Deal Size : Undisclosed
Deal Type : Partnership
RheumaGen and SiVEC Announce CGT Partnership and In Vivo Program
Details : As part of the partnership, RG0401, a cell & gene therapy targeting HLA, aims to address Rheumatoid Arthritis.
Product Name : RG0401
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 07, 2025
Lead Product(s) : RG0401
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : RheumaGen
Deal Size : Undisclosed
Deal Type : Partnership
